WIPO – 检索国际和国家专利汇编

1.20240156972ANTIBODY RECRUITMENT MOLECULES AND METHODS OF TREATING CANCER USING SAME

US - 16.05.2024

国际分类 A61K 47/64 申请号 18547714 申请人 McMaster University 发明人 Anthony RULLO

The present disclosure relates generally to the field of cancer immunotherapy. More particularly, the present disclosure provides antibody recruitment molecules, pharmaceutical compositions comprising same and kits comprising same. The present disclosure also provides methods of treating cancer using the antibody recruitment molecules in combination with oncolytic virus therapy, and methods for enhancing the efficacy and/or reducing the toxicity of the oncolytic virus therapy.

2.WO/2024/102079COMPOSITIONS COMPRISING POLYINOSINIC-POLYCYTIDYLIC ACID, EPSTEIN-BARR (EBV) VIRUS-LIKE PARTICLES AND EBV-SPECIFIC CAR-T CELLS FOR IMPROVING IMMUNE CELL THERAPY

WO - 16.05.2024

国际分类 A61K 31/7088 申请号 PCT/SG2023/050746 申请人 ZENO THERAPEUTICS PTE LTD 发明人 LI, Lietao, Victor

The disclosure relates to an immunogenic composition comprising polyinosinic-polycytidylic acid (PIC), a stabilizer comprising an aminoglycoside or non- aminoglycoside antibiotic, at least one cation and optionally, an immunogen. It also relates an immunogenic composition comprising Epstein-Barr (EBV) virus-like particles. It further describes EBV- specific CAR-T cells and the use of the immunogenic composition comprising PIC alone or in combination with VLP or CAR-T cells for the treatment of cancer.

3.20240156730HYDROXYETHYCELLULOSE GEL COMPOSITION COMPRISING BACTERIOPHAGES

US - 16.05.2024

国际分类 A61K 9/06 申请号 18349058 申请人 PhaTEC GmbH 发明人 Simon Frank Junghans

The present invention provides a hydrogel comprising hydroxyethyl cellulose (HEC) and bacteriophages.

4.WO/2024/096738GENE THERAPY CONSTRUCTS FOR METABOLIC DISORDERS

WO - 10.05.2024

国际分类 A61K 35/76 申请号 PCT/NL2023/050576 申请人 ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM 发明人 PIJNAPPEL, Wilhelmus Wenceslaus Matthias

The invention relates to nucleic acid molecules comprising a nucleotide sequence encoding a metabolic protein or a part thereof or a sequence having at least 90% sequence identity to said metabolic protein or part thereof, a human insulin-like growth factor II (IGFII) gene sequence, and a nucleotide sequence encoding at least one peptide that facilitates cellular uptake or transcytosis which is inserted at a location between the nucleotides encoding amino acids 28 and 42 of mature IGFII of said IGFII gene sequence. The invention further relates to related viral particles, fusion proteins and uses thereof.

5.WO/2024/095209MINISTRING DNA FOR PRODUCING ADENO-ASSOCIATED VIRUS

WO - 10.05.2024

国际分类 C12N 15/864 申请号 PCT/IB2023/061082 申请人 MEDIPHAGE BIOCEUTICALS, INC. 发明人 SLAVCEV, Roderick

Provided herein are expression vectors, vector production systems, bacterial sequence- free vectors, and methods for producing adeno-associated viruses (AAVs). Also provided are AAVs as well as pharmaceutical compositions and uses thereof.

6.20240148806BACTERIOPHAGES PRODUCING HETEROLOGOUS BACTERIOCINS

US - 09.05.2024

国际分类 A61K 35/76 申请号 18344998 申请人 ETH Zurich 发明人 Samuel Nando KILCHER

The present invention relates to the field of medicine, specifically the field of bacterial infection and treatment thereof.

7.0002818910METHOD FOR PREVENTION OF HEALTHCARE-ASSOCIATED INFECTIONS IN PATIENTS IN CHRONIC CRITICAL CONDITION

RU - 07.05.2024

国际分类 A61P 31/04 申请号 2023122530 申请人发明人 Гречко Андрей Вячеславович (RU)

FIELD: medicine. SUBSTANCE: method for preventing infections associated with the provision of medical care in patients in a chronic critical condition relates to medicine, namely to anaesthesiology-resuscitation, and can be used for prevention of healthcare-associated infections (HAI), in patients with high risk of infectious complications in chronic critical condition (CCC). Patient belongs to the HAI risk group by molecular genetic analysis of potential infectious agents and their resistance genes in bronchoalveolar lavage (BAL), or sputum, or endotracheal aspirate (ETA), as well as in intestinal contents by polymerase chain reaction on the first day of admission to hospital. Risk of HAI is determined by detecting ESKAPE microorganisms in titre of more than 104 CFU/ml, genes of resistance to beta-lactam and glycopeptide antibiotics in DNA preparations obtained from the analysed human preparation, intestinal dysbiosis. Prevention of HAI is performed by inhalation introduction of a basic complex of bacteriophages containing phages, which are active against bacteria, the main pathogens of HAI of the respiratory tract, obtained from the biomaterial of the patients of the given institution, which is adapted to a specific department. And also by oral administration of a basic bacteriophage complex containing phages, which are active against bacteria of the main HAI pathogens, obtained from the biomaterial of the patients of the given institution, colonizing the intestine, adapted to a specific department. Ready form containing an adapted composition of bacteriophages, which is an active substance in the form of a mixture of sterile purified bacteriophages in a Gratia concentration of 104–9.9×107 PFU/cm3 in 1 ml, excipient in the form of physiological saline up to 5 ml is administered by inhalation to patients in dose of 5 ml 2-3 times a day for at least 7 days. As well as a ready-made form containing an adapted composition of bacteriophages, which is an active substance in the form of a mixture of sterile purified bacteriophages in concentration Gratia 104–9.90×107 PFU/cm3 in 1 ml, excipient in the form of physiological solution up to 10 ml is administered orally in dose of 10.0 ml 2 times a day for at least 7 days. EFFECT: invention provides determining whether a patient belongs to a risk group for the occurrence of infectious complications, is universal and independent of classical labour-intensive and time-consuming microbiological methods. 1 cl, 1 tbl, 3 ex

8.117965461一种功能增强型溶瘤病毒及制备方法与应用

CN - 03.05.2024

国际分类 C12N 7/01 申请号 202311808150.0 申请人国科温州研究院（温州生物材料与工程研究所）发明人夏玉龙

一种功能增强型溶瘤病毒及制备方法与应用，该溶瘤病毒携带可调控DTA基因表达的Tet‑On基因表达调控系统，病毒包装过程中Tet‑On系统保持关闭状态，从而避免溶瘤腺病毒包装和扩增过程中DTA的表达对HEK293细胞的“误伤”，溶瘤腺病毒注射治疗初期仍然保持Tet‑On系统关闭，待病毒在肿瘤内扩增一段时间后，通过强力霉素诱导感染病毒细胞内DTA的表达，从而增强抗肿瘤功效，同时该方法降低病毒使用剂量，降低溶瘤病毒可能引起的不良反应，携带DTA的溶瘤腺病毒治疗初期出现不了反应，可及时开启DTA基因表达杀死感染初期的宿主细胞，有助于机体快速清除暴露的溶瘤腺病毒，从而起到降低溶瘤病毒治疗风险的作用。

9.117959345Nrxn3激动剂在制备预防或治疗NASH及相关疾病的药物中的应用

CN - 03.05.2024

国际分类 A61K 35/761 申请号 202410125210.7 申请人江苏省人民医院（南京医科大学第一附属医院）发明人孙伟

本发明公开了在NASH小鼠的PVN过表达NRXN3可以改善小鼠高脂高糖高胆固醇饮食所增加的体重且与进食量无关，还可以改善NASH小鼠的AST,ALT，LDL,TC，以及糖耐量。还可以改善NASH小鼠的肝脏形态，肝重以及肝脏TG含量。以上均提示Nrxn3激动剂可以预防或治疗NASH及相关疾病。

10.117965457一种噬菌体及其应用

CN - 03.05.2024

国际分类 C12N 7/00 申请号 202311727130.0 申请人广州医科大学发明人陈萍

本发明属于生物医药技术领域，主要涉及噬菌体及其应用。本发明提供一种噬菌体，其保藏编号为GDMCC No:64029‑B1，当大蒜素与该噬菌体联用，二者有协同抗铜绿假单胞菌的作用，且联用后两种物质的用量都有大幅度的减少。面对目前抗生素滥用导致的耐药菌，这种联用不仅可以有效对抗感染，还可以在一定程度上减少抗生素的使用，减轻抗生素滥用带来的压力。

1 / 1,190

转到检索输入栏	`CTRL` + `SHIFT` +
转到结果（选定结果）	`CTRL` + `SHIFT` +
转到详细信息（选定标签）	`CTRL` + `SHIFT` +
转到下一页	`CTRL` +
转到上一页	`CTRL` +

转到下一个结果/图像	/
转到上一个结果/图像	/
向上滚动	`Page Up`
向下滚动	`Page Down`
滚动至顶部	`CTRL` + `Home`
滚动至底部	`CTRL` + `End`

正在处理

进入国家阶段

规范文件

设置

反馈

查看申请

保存查询

查询树

优化选项

完整查询

并排视图快捷键

分析

转到下一个标签
转到上一个标签